DC 6002 — Scleritis
Rating-schedule reference for Scleritis. Service connection and severity are different questions.
Inspect the official criteria
Open 38 CFR 4.79, DC 6002 on eCFRCode identity and containing source text compared with eCFR text as of October 1, 2026. Interpretation and document relationships have separate review coverage.
Containing regulation — source text as of October 1, 2026
Diseases of the Eye
| Rating | |
|---|---|
| General Rating Formula for Diseases of the Eye: | |
| Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation | |
| With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months | 60 |
| With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months | 40 |
| With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months | 20 |
| With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months | 10 |
| Note (1): For the purposes of evaluation under 38 CFR 4.79 , an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes | |
| Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions | |
| Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79 , diagnostic codes 6061-6091 | |
| 6000 Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. | |
| 6001 Keratopathy. | |
| 6002 Scleritis. | |
| 6006 Retinopathy or maculopathy not otherwise specified | |
| 6007 Intraocular hemorrhage. | |
| 6008 Detachment of retina. | |
| 6009 Unhealed eye injury. | |
| Note: This code includes orbital trauma, as well as penetrating or non-penetrating eye injury | |
| 6010 Tuberculosis of eye: | |
| Active | 100 |
| Inactive: Evaluate under § 4.88c or § 4.89 of this part , whichever is appropriate | |
| 6011 Retinal scars, atrophy, or irregularities: | |
| Localized scars, atrophy, or irregularities of the retina, unilateral or bilateral, that are centrally located and that result in an irregular, duplicated, enlarged, or diminished image | 10 |
| Alternatively, evaluate based on the General Rating Formula for Diseases of the Eye, if this would result in a higher evaluation | |
| 6012 Angle-closure glaucoma | |
| Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required | 10 |
| 6013 Open-angle glaucoma | |
| Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required | 10 |
| 6014 Malignant neoplasms of the eye, orbit, and adnexa (excluding skin): | |
| Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation | 100 |
| Note: Continue the 100 percent rating beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating will be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e) of this chapter . If there has been no local recurrence or metastasis, evaluate based on residuals | |
| Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that do not require therapy comparable to that for systemic malignancies: | |
| Separately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations | |
| 6015 Benign neoplasms of the eye, orbit, and adnexa (excluding skin): | |
| Separately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations | |
| 6016 Nystagmus, central | 10 |
| 6017 Trachomatous conjunctivitis: | |
| Active: Evaluate under the General Rating Formula for Diseases of the Eye, minimum rating | 30 |
| Inactive: Evaluate based on residuals, such as visual impairment and disfigurement (diagnostic code 7800) | |
| 6018 Chronic conjunctivitis (nontrachomatous): | |
| Active: Evaluate under the General Rating Formula for Diseases of the Eye, minimum rating | 10 |
| Inactive: Evaluate based on residuals, such as visual impairment and disfigurement (diagnostic code 7800) | |
| 6019 Ptosis, unilateral or bilateral: | |
| Evaluate based on visual impairment or, in the absence of visual impairment, on disfigurement (diagnostic code 7800). | |
| 6020 Ectropion: | |
| Bilateral | 20 |
| Unilateral | 10 |
| 6021 Entropion: | |
| Bilateral | 20 |
| Unilateral | 10 |
| 6022 Lagophthalmos: | |
| Bilateral | 20 |
| Unilateral | 10 |
| 6023 Loss of eyebrows, complete, unilateral or bilateral | 10 |
| 6024 Loss of eyelashes, complete, unilateral or bilateral | 10 |
| 6025 Disorders of the lacrimal apparatus (epiphora, dacryocystitis, etc.): | |
| Bilateral | 20 |
| Unilateral | 10 |
| 6026 Optic neuropathy | |
| 6027 Cataract: | |
| Preoperative: Evaluate under the General Rating Formula for Diseases of the Eye | |
| Postoperative: If a replacement lens is present (pseudophakia), evaluate under the General Rating Formula for Diseases of the Eye. If there is no replacement lens, evaluate based on aphakia (diagnostic code 6029) | |
| 6029 Aphakia or dislocation of crystalline lens: | |
| Evaluate based on visual impairment, and elevate the resulting level of visual impairment one step. | |
| Minimum (unilateral or bilateral) | 30 |
| 6030 Paralysis of accommodation (due to neuropathy of the Oculomotor Nerve (cranial nerve III)). | 20 |
| 6032 Loss of eyelids, partial or complete: | |
| Separately evaluate both visual impairment due to eyelid loss and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations. | |
| 6034 Pterygium: | |
| Evaluate under the General Rating Formula for Diseases of the Eye, disfigurement (diagnostic code 7800), conjunctivitis (diagnostic code 6018), etc., depending on the particular findings, and combine in accordance with § 4.25 | |
| 6035 Keratoconus | |
| 6036 Status post corneal transplant: | |
| Evaluate under the General Rating Formula for Diseases of the Eye. Minimum, if there is pain, photophobia, and glare sensitivity | 10 |
| 6037 Pinguecula: | |
| Evaluate based on disfigurement (diagnostic code 7800). | |
| 6040 Diabetic retinopathy | |
| 6042 Retinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset macular degeneration, rod and/or cone dystrophy) | |
| 6046 Post-chiasmal disorders |
Impairment of Central Visual Acuity
| Criterion / instruction | Source value |
|---|---|
| 6061 Anatomical loss of both eyes ^{1} | 100 |
| 6062 No more than light perception in both eyes ^{1} | 100 |
| 6063 Anatomical loss of one eye: ^{1} | |
| In the other eye 5/200 (1.5/60) | 100 |
| In the other eye 10/200 (3/60) | 90 |
| In the other eye 15/200 (4.5/60) | 80 |
| In the other eye 20/200 (6/60) | 70 |
| In the other eye 20/100 (6/30) | 60 |
| In the other eye 20/70 (6/21) | 60 |
| In the other eye 20/50 (6/15) | 50 |
| In the other eye 20/40 (6/12) | 40 |
| 6064 No more than light perception in one eye: ^{1} | |
| In the other eye 5/200 (1.5/60) | 100 |
| In the other eye 10/200 (3/60) | 90 |
| In the other eye 15/200 (4.5/60) | 80 |
| In the other eye 20/200 (6/60) | 70 |
| In the other eye 20/100 (6/30) | 60 |
| In the other eye 20/70 (6/21) | 50 |
| In the other eye 20/50 (6/15) | 40 |
| In the other eye 20/40 (6/12) | 30 |
| 6065 Vision in one eye 5/200 (1.5/60): | |
| In the other eye 5/200 (1.5/60) | ^{1} 100 |
| In the other eye 10/200 (3/60) | 90 |
| In the other eye 15/200 (4.5/60) | 80 |
| In the other eye 20/200 (6/60) | 70 |
| In the other eye 20/100 (6/30) | 60 |
| In the other eye 20/70 (6/21) | 50 |
| In the other eye 20/50 (6/15) | 40 |
| In the other eye 20/40 (6/12) | 30 |
| 6066 Visual acuity in one eye 10/200 (3/60) or better: | |
| Vision in one eye 10/200 (3/60): | |
| In the other eye 10/200 (3/60) | 90 |
| In the other eye 15/200 (4.5/60) | 80 |
| In the other eye 20/200 (6/60) | 70 |
| In the other eye 20/100 (6/30) | 60 |
| In the other eye 20/70 (6/21) | 50 |
| In the other eye 20/50 (6/15) | 40 |
| In the other eye 20/40 (6/12) | 30 |
| Vision in one eye 15/200 (4.5/60): | |
| In the other eye 15/200 (4.5/60) | 80 |
| In the other eye 20/200 (6/60) | 70 |
| In the other eye 20/100 (6/30) | 60 |
| In the other eye 20/70 (6/21) | 40 |
| In the other eye 20/50 (6/15) | 30 |
| In the other eye 20/40 (6/12) | 20 |
| Vision in one eye 20/200 (6/60): | |
| In the other eye 20/200 (6/60) | 70 |
| In the other eye 20/100 (6/30) | 60 |
| In the other eye 20/70 (6/21) | 40 |
| In the other eye 20/50 (6/15) | 30 |
| In the other eye 20/40 (6/12) | 20 |
| Vision in one eye 20/100 (6/30): | |
| In the other eye 20/100 (6/30) | 50 |
| In the other eye 20/70 (6/21) | 30 |
| In the other eye 20/50 (6/15) | 20 |
| In the other eye 20/40 (6/12) | 10 |
| Vision in one eye 20/70 (6/21): | |
| In the other eye 20/70 (6/21) | 30 |
| In the other eye 20/50 (6/15) | 20 |
| In the other eye 20/40 (6/12) | 10 |
| Vision in one eye 20/50 (6/15): | |
| In the other eye 20/50 (6/15) | 10 |
| In the other eye 20/40 (6/12) | 10 |
| Vision in one eye 20/40 (6/12): | |
| In the other eye 20/40 (6/12) | 0 |
^{1} Review for entitlement to special monthly compensation under 38 CFR 3.350 .
Ratings for Impairment of Visual Fields
| Rating | |
|---|---|
| 6080 Visual field defects: | |
| Homonymous hemianopsia | 30 |
| Loss of temporal half of visual field: | |
| Bilateral | 30 |
| Unilateral | 10 |
| Or evaluate each affected eye as 20/70 (6/21) | |
| Loss of nasal half of visual field: | |
| Bilateral | 10 |
| Unilateral | 10 |
| Or evaluate each affected eye as 20/50 (6/15) | |
| Loss of inferior half of visual field: | |
| Bilateral | 30 |
| Unilateral | 10 |
| Or evaluate each affected eye as 20/70 (6/21) | |
| Loss of superior half of visual field: | |
| Bilateral | 10 |
| Unilateral | 10 |
| Or evaluate each affected eye as 20/50 (6/15) | |
| Concentric contraction of visual field: | |
| With remaining field of 5 degrees: ^{1} | |
| Bilateral | 100 |
| Unilateral | 30 |
| Or evaluate each affected eye as 5/200 (1.5/60) | |
| With remaining field of 6 to 15 degrees: | |
| Bilateral | 70 |
| Unilateral | 20 |
| Or evaluate each affected eye as 20/200 (6/60) | |
| With remaining field of 16 to 30 degrees: | |
| Bilateral | 50 |
| Unilateral | 10 |
| Or evaluate each affected eye as 20/100 (6/30) | |
| With remaining field of 31 to 45 degrees: | |
| Bilateral | 30 |
| Unilateral | 10 |
| Or evaluate each affected eye as 20/70 (6/21) | |
| With remaining field of 46 to 60 degrees: | |
| Bilateral | 10 |
| Unilateral | 10 |
| Or evaluate each affected eye as 20/50 (6/15) | |
| 6081 Scotoma, unilateral: | |
| Minimum, with scotoma affecting at least one-quarter of the visual field (quadrantanopsia) or with centrally located scotoma of any size | 10 |
| Alternatively, evaluate based on visual impairment due to scotoma, if that would result in a higher evaluation |
^{1} Review for entitlement to special monthly compensation under 38 CFR 3.350 .
Ratings for Impairment of Muscle Function
| Degree of diplopia | Equivalent |
|---|
visual acuity
| Criterion / instruction | |
|---|---|
| 6090 Diplopia (double vision): | |
| (a) Central 20 degrees | 5/200 (1.5/60) |
| (b) 21 degrees to 30 degrees | |
| (1) Down | 15/200 (4.5/60) |
| (2) Lateral | 20/100 (6/30) |
| (3) Up | 20/70 (6/21) |
| (c) 31 degrees to 40 degrees | |
| (1) Down | 20/200 (6/60) |
| (2) Lateral | 20/70 (6/21) |
| (3) Up | 20/40 (6/12) |
| Note: In accordance with 38 CFR 4.31 , diplopia that is occasional or that is correctable with spectacles is evaluated at 0 percent. | |
| 6091 Symblepharon: | |
| Evaluate under the General Rating Formula for Diseases of the Eye, lagophthalmos (diagnostic code 6022), disfigurement (diagnostic code 7800), etc., depending on the particular findings, and combine in accordance with § 4.25 |
(Authority: 38 U.S.C. 1155 )
[73 FR 66550 , Nov. 10, 2008, as amended at 83 FR 15321 , Apr. 10, 2018]
Annual 2025 archive
Diseases of the Eye Rating General Rating Formula for Diseases of the Eye: Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation With documented incapacitating episodes requiring 7 or more treatment visits for an eye condition during the past 12 months 60 With documented incapacitating episodes requiring at least 5 but less than 7 treatment visits for an eye condition during the past 12 months 40 With documented incapacitating episodes requiring at least 3 but less than 5 treatment visits for an eye condition during the past 12 months 20 With documented incapacitating episodes requiring at least 1 but less than 3 treatment visits for an eye condition during the past 12 months 10 Note (1): For the purposes of evaluation under 38 CFR 4.79, an incapacitating episode is an eye condition severe enough to require a clinic visit to a provider specifically for treatment purposes Note (2): Examples of treatment may include but are not limited to: Systemic immunosuppressants or biologic agents; intravitreal or periocular injections; laser treatments; or other surgical interventions Note (3): For the purposes of evaluating visual impairment due to the particular condition, refer to 38 CFR 4.75-4.78 and to § 4.79, diagnostic codes 6061-6091 6000 Choroidopathy, including uveitis, iritis, cyclitis, or choroiditis. 6001 Keratopathy. 6002 Scleritis. 6006 Retinopathy or maculopathy not otherwise specified 6007 Intraocular hemorrhage. 6008 Detachment of retina. 6009 Unhealed eye injury. Note: This code includes orbital trauma, as well as penetrating or non-penetrating eye injury 6010 Tuberculosis of eye: Active 100 Inactive: Evaluate under § 4.88c or § 4.89 of this part, whichever is appropriate 6011 Retinal scars, atrophy, or irregularities: Localized scars, atrophy, or irregularities of the retina, unilateral or bilateral, that are centrally located and that result in an irregular, duplicated, enlarged, or diminished image 10 Alternatively, evaluate based on the General Rating Formula for Diseases of the Eye, if this would result in a higher evaluation 6012 Angle-closure glaucoma Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required 10 6013 Open-angle glaucoma Evaluate under the General Rating Formula for Diseases of the Eye. Minimum evaluation if continuous medication is required 10 6014 Malignant neoplasms of the eye, orbit, and adnexa (excluding skin): Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that require therapy that is comparable to those used for systemic malignancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation 100 Note: Continue the 100 percent rating beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating will be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination will be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, evaluate based on residuals Malignant neoplasms of the eye, orbit, and adnexa (excluding skin) that do not require therapy comparable to that for systemic malignancies: Separately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations 6015 Benign neoplasms of the eye, orbit, and adnexa (excluding skin): Separately evaluate visual and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations 6016 Nystagmus, central 10 6017 Trachomatous conjunctivitis: Active: Evaluate under the General Rating Formula for Diseases of the Eye, minimum rating 30 Inactive: Evaluate based on residuals, such as visual impairment and disfigurement (diagnostic code 7800) 6018 Chronic conjunctivitis (nontrachomatous): Active: Evaluate under the General Rating Formula for Diseases of the Eye, minimum rating 10 Inactive: Evaluate based on residuals, such as visual impairment and disfigurement (diagnostic code 7800) 6019 Ptosis, unilateral or bilateral: Evaluate based on visual impairment or, in the absence of visual impairment, on disfigurement (diagnostic code 7800). 6020 Ectropion: Bilateral 20 Unilateral 10 6021 Entropion: Bilateral 20 Unilateral 10 6022 Lagophthalmos: Bilateral 20 Unilateral 10 6023 Loss of eyebrows, complete, unilateral or bilateral 10 6024 Loss of eyelashes, complete, unilateral or bilateral 10 6025 Disorders of the lacrimal apparatus (epiphora, dacryocystitis, etc.): Bilateral 20 Unilateral 10 6026 Optic neuropathy 6027 Cataract: Preoperative: Evaluate under the General Rating Formula for Diseases of the Eye Postoperative: If a replacement lens is present (pseudophakia), evaluate under the General Rating Formula for Diseases of the Eye. If there is no replacement lens, evaluate based on aphakia (diagnostic code 6029) 6029 Aphakia or dislocation of crystalline lens: Evaluate based on visual impairment, and elevate the resulting level of visual impairment one step. Minimum (unilateral or bilateral) 30 6030 Paralysis of accommodation (due to neuropathy of the Oculomotor Nerve (cranial nerve III)). 20 6032 Loss of eyelids, partial or complete: Separately evaluate both visual impairment due to eyelid loss and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations. 6034 Pterygium: Evaluate under the General Rating Formula for Diseases of the Eye, disfigurement (diagnostic code 7800), conjunctivitis (diagnostic code 6018), etc., depending on the particular findings, and combine in accordance with § 4.25 6035 Keratoconus 6036 Status post corneal transplant: Evaluate under the General Rating Formula for Diseases of the Eye. Minimum, if there is pain, photophobia, and glare sensitivity 10 6037 Pinguecula: Evaluate based on disfigurement (diagnostic code 7800). 6040 Diabetic retinopathy 6042 Retinal dystrophy (including retinitis pigmentosa, wet or dry macular degeneration, early-onset macular degeneration, rod and/or cone dystrophy) 6046 Post-chiasmal disorders Impairment of Central Visual Acuity 6061 Anatomical loss of both eyes 1 100 6062 No more than light perception in both eyes 1 100 6063 Anatomical loss of one eye: 1 In the other eye 5/200 (1.5/60) 100 In the other eye 10/200 (3/60) 90 In the other eye 15/200 (4.5/60) 80 In the other eye 20/200 (6/60) 70 In the other eye 20/100 (6/30) 60 In the other eye 20/70 (6/21) 60 In the other eye 20/50 (6/15) 50 In the other eye 20/40 (6/12) 40 6064 No more than light perception in one eye: 1 In the other eye 5/200 (1.5/60) 100 In the other eye 10/200 (3/60) 90 In the other eye 15/200 (4.5/60) 80 In the other eye 20/200 (6/60) 70 In the other eye 20/100 (6/30) 60 In the other eye 20/70 (6/21) 50 In the other eye 20/50 (6/15) 40 In the other eye 20/40 (6/12) 30 6065 Vision in one eye 5/200 (1.5/60): In the other eye 5/200 (1.5/60) 1 100 In the other eye 10/200 (3/60) 90 In the other eye 15/200 (4.5/60) 80 In the other eye 20/200 (6/60) 70 In the other eye 20/100 (6/30) 60 In the other eye 20/70 (6/21) 50 In the other eye 20/50 (6/15) 40 In the other eye 20/40 (6/12) 30 6066 Visual acuity in one eye 10/200 (3/60) or better: Vision in one eye 10/200 (3/60): In the other eye 10/200 (3/60) 90 In the other eye 15/200 (4.5/60) 80 In the other eye 20/200 (6/60) 70 In the other eye 20/100 (6/30) 60 In the other eye 20/70 (6/21) 50 In the other eye 20/50 (6/15) 40 In the other eye 20/40 (6/12) 30 Vision in one eye 15/200 (4.5/60): In the other eye 15/200 (4.5/60) 80 In the other eye 20/200 (6/60) 70 In the other eye 20/100 (6/30) 60 In the other eye 20/70 (6/21) 40 In the other eye 20/50 (6/15) 30 In the other eye 20/40 (6/12) 20 Vision in one eye 20/200 (6/60): In the other eye 20/200 (6/60) 70 In the other eye 20/100 (6/30) 60 In the other eye 20/70 (6/21) 40 In the other eye 20/50 (6/15) 30 In the other eye 20/40 (6/12) 20 Vision in one eye 20/100 (6/30): In the other eye 20/100 (6/30) 50 In the other eye 20/70 (6/21) 30 In the other eye 20/50 (6/15) 20 In the other eye 20/40 (6/12) 10 Vision in one eye 20/70 (6/21): In the other eye 20/70 (6/21) 30 In the other eye 20/50 (6/15) 20 In the other eye 20/40 (6/12) 10 Vision in one eye 20/50 (6/15): In the other eye 20/50 (6/15) 10 In the other eye 20/40 (6/12) 10 Vision in one eye 20/40 (6/12): In the other eye 20/40 (6/12) 0 1 Review for entitlement to special monthly compensation under 38 CFR 3.350. Ratings for Impairment of Visual Fields Rating 6080 Visual field defects: Homonymous hemianopsia 30 Loss of temporal half of visual field: Bilateral 30 Unilateral 10 Or evaluate each affected eye as 20/70 (6/21) Loss of nasal half of visual field: Bilateral 10 Unilateral 10 Or evaluate each affected eye as 20/50 (6/15) Loss of inferior half of visual field: Bilateral 30 Unilateral 10 Or evaluate each affected eye as 20/70 (6/21) Loss of superior half of visual field: Bilateral 10 Unilateral 10 Or evaluate each affected eye as 20/50 (6/15) Concentric contraction of visual field: With remaining field of 5 degrees: 1 Bilateral 100 Unilateral 30 Or evaluate each affected eye as 5/200 (1.5/60) With remaining field of 6 to 15 degrees: Bilateral 70 Unilateral 20 Or evaluate each affected eye as 20/200 (6/60) With remaining field of 16 to 30 degrees: Bilateral 50 Unilateral 10 Or evaluate each affected eye as 20/100 (6/30) With remaining field of 31 to 45 degrees: Bilateral 30 Unilateral 10 Or evaluate each affected eye as 20/70 (6/21) With remaining field of 46 to 60 degrees: Bilateral 10 Unilateral 10 Or evaluate each affected eye as 20/50 (6/15) 6081 Scotoma, unilateral: Minimum, with scotoma affecting at least one-quarter of the visual field (quadrantanopsia) or with centrally located scotoma of any size 10 Alternatively, evaluate based on visual impairment due to scotoma, if that would result in a higher evaluation 1 Review for entitlement to special monthly compensation under 38 CFR 3.350. Ratings for Impairment of Muscle Function Degree of diplopia Equivalent visual acuity 6090 Diplopia (double vision): (a) Central 20 degrees 5/200 (1.5/60) (b) 21 degrees to 30 degrees (1) Down 15/200 (4.5/60) (2) Lateral 20/100 (6/30) (3) Up 20/70 (6/21) (c) 31 degrees to 40 degrees (1) Down 20/200 (6/60) (2) Lateral 20/70 (6/21) (3) Up 20/40 (6/12) Note: In accordance with 38 CFR 4.31, diplopia that is occasional or that is correctable with spectacles is evaluated at 0 percent. 6091 Symblepharon: Evaluate under the General Rating Formula for Diseases of the Eye, lagophthalmos (diagnostic code 6022), disfigurement (diagnostic code 7800), etc., depending on the particular findings, and combine in accordance with § 4.25 (Authority: 38 U.S.C. 1155) [73 FR 66550, Nov. 10, 2008, as amended at 83 FR 15321, Apr. 10, 2018]
Original annual CFR source